News & Updates

Treatment with nirmatrelvir/ritonavir (NMV/r) provides good value for money because of its health benefits for patients with mild-to-moderate COVID-19 who are at an increased risk of progressing to severe disease, according to the results of a systematic literature review of economic value.

Treatment with nirmatrelvir/ritonavir significantly reduced mortality risk among hospitalized COVID-19 patients compared with the combined molnupiravir and nirmatrelvir/ritonavir regimen, according to a target trial emulation study presented at IDWeek 2025.

Treatment with nirmatrelvir/ritonavir (NMV/r) reduced both the duration and severity of COVID-19 symptoms, based on patients’ overall perception of their symptom burden, and facilitated a faster return to normal health and activities, as demonstrated in a recent exploratory analysis.

In young children with type 1 diabetes (T1D), bedtime snacking appears to result in higher nocturnal glucose values and reduced time in range (TIR), without decreasing the frequency of hypoglycaemia, according to a randomized controlled crossover trial.

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

An elevated matrix metalloproteinase-9 (MMP-9) appears to cause lung function decline and the development of chronic obstructive pulmonary disease (COPD), suggests a study.

Psychiatric patients exposed to doxycycline appear to have a reduced risk of schizophrenia, according to a study.